Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 69 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Leveraging in-depth analyst evaluations, we have synthesized critical insights from expert assessments to deliver a robust outlook for AAVXF. Our analysts highlight strong fundamentals and favorable market sentiment, positioning AAVXF for significant upside potential in the near term. Based on this comprehensive expert analysis, we maintain a highly optimistic view of this stock. Our conclusion: AAVXF is a Strong Buy candidate.
AAVXF stock price ended at $120.85 on 木曜日, after rising 0.16%
On the latest trading day Jan 15, 2026, the stock price of AAVXF rose by 0.16%, climbing from $120.85 to $120.85. Throughout the session, the stock experienced a volatility of 0.00%, with prices fluctuating between a daily low of $120.85 and a high of $120.85. Alongside this price increase, trading volume also rose by 82 shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 118 shares were traded, amounting to a market value of approximately $9.4B.